Remsima Case Study – The importance of ADCC in assessing clinically relevant differences

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules. One area of interest recently has been the subject of extrapolation of data from one clinical trial within a specific indication to one or more alternative indications. This will become more and more critical as manufacturers seek to maximise the potential patient population and recoup development costs as new versions of the biosimilars enter the market.

In order to access this document, we first require some information from you.

By submitting your details to download our resources you are agreeing to the processing of your personal information for these purposes in accordance with our privacy policy.

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy